Skip to content

Author

Jaime Fuentealba

We have 1 of 11 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

[In vivo CAR-T cells: When the patient becomes their own factory].

The main delivery platforms under clinical investigation are described, focusing on lentiviral vectors and lipid nanoparticles, and their differences in terms of mechanisms of action, associated risks, and optimization strategies are discussed.

François Vilcot, Carole-Anne Brugère, Jaime Fuentealba et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.